NRx started at Buy by Wainwright

 

• HC Wainwright initiated coverage on NRx Pharmaceuticals Inc 
  NRXP-6.33%+ Free Alerts
   with a Buying rating and a price target of $2.
• Earlier today, the FDA declined to issue an Emergency Use Authorization for NRx's Zyesami for a subgroup of patients who also received Gilead Sciences Inc's 
  GILD+0.89%+ Free Alerts
   remdesivir in addition to Zyesami.
• The analyst is bullish on:
  • Significant potential for NRX-101 for bipolar depressed patients that can rapidly stabilize patients with suicidal ideation and behavior. "We believe NRx's focus on treatments for bipolar depression with SIB makes NRx a leader in drug development in this field," HC Wainwright notes.
  • Zyesami's nascent value as a novel potential therapy for acute and chronic lung disorders. 
• "We believe uncertainty in the Zyesami clinical program has been priced into NRx stock, representing a value proposition ahead of key clinical milestones that could potentially lead to NRX-101 approval in 2024", the analysts added.

https://www.benzinga.com/general/biotech/22/07/27935215/hc-wainwright-finds-synergies-in-treatment-for-this-bipolar-focused-stock